Data on a hyaluronic acid filler for chin shaping, a biostimulator for medication-driven weight loss effects, and a liquid neuromodulator will be presented at the upcoming AMWC Dubai.
Galderma will present new data from its injectable aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Dubai, scheduled for Oct 1-3, 2025. The presentations will include post-marketing data on a hyaluronic acid (HA) filler for the chin, findings on a biostimulator for facial volume loss associated with weight loss medications, and Phase III results for a ready-to-use liquid neuromodulator.
HA Filler and Biostimulator Data
Post-marketing data from the ARTIST study on Restylane Shaype, an HA injectable, will be shared. The data supports the product’s use in the chin region, both alone and in combination with other fillers. According to the results, investigators and patients agreed that 100% of patients experienced aesthetic improvement at four and eight weeks post-injection. At week eight, 100% of patients also reported improved chin definition and natural-looking results.
The company will also present results from an expert consensus on Sculptra, a regenerative biostimulator, detailing its effects on fibroblast activation and the stimulation of collagen and elastin.
Additionally, three-month data will be presented on the combined use of Sculptra with Restylane Lyft or Contour to address facial volume loss in patients who have experienced medication-driven weight loss. The study found that the combination regimen improved skin quality beyond simple volumization, with Restylane Lyft improving skin hydration and Sculptra improving skin radiance and thickness.
“The exponential rise in the use of prescription weight loss medications has prompted the medical aesthetics community to quickly adapt to understand the related aesthetic needs,” says Michael Somenek, MD, a facial plastic surgeon in Washington DC, in a release. “This is why having a platform at AMWC Dubai is so important to enable us to share the latest insights on addressing the unique aesthetic concerns of these patients, such as data showing how the benefits of Sculptra and Restylane can work together to enhance skin quality and emotional well-being.”
In conjunction with these findings, Galderma will host a symposium titled “Aesthetic Changes in Medication-Driven Weight Loss: The Algorithms” featuring live demonstrations.
Ready-to-Use Liquid Neuromodulator
Data from four studies in the Phase III READY clinical trial program for Relfydess (RelabotulinumtoxinA), a ready-to-use liquid neuromodulator, will also be presented. The formulation eliminates the need for reconstitution.
For the treatment of both frown lines and crow’s feet, combined results showed an onset of action as early as day one and a duration of effect through six months. Subjects in the studies also reported consistently high satisfaction. RelabotulinumtoxinA is an investigational drug product in the US.
ID 159440306 © Iryna Gyrych | Dreamstime.com
